Lecithin based treatment for Colitis ulcerosa

摘要

Lipid Therapeutics, a biopharma company in Heidelberg, Germany, initiated a phase IIb clinical study with their phospholipid-based product for Colitis ulcerosa treatment. The formulation named LT-02 contains phosphatidylcholine as the main component, and its mechanism of action should be by improving the barrier function of the mucosa in the lumen of the colon.